Format

Send to

Choose Destination
ACS Med Chem Lett. 2012 Mar 2;3(4):332-6. doi: 10.1021/ml300017p. eCollection 2012 Apr 12.

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.

Author information

1
Departments of Medicinal Chemistry, Drug Metabolism, and Molecular Modeling, IRBM, Merck Research Laboratories , Rome, Italy.
2
Departments of Medicinal Chemistry, Antiviral Research, Drug Metabolism, and Chemistry, Modeling and Informatics, Merck Research Laboratories , West Point, Pennsylvania 19486, United States.

Abstract

A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clinically relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.

KEYWORDS:

HCV; MK-5172; genotype 3a; hepatitis C; macrocycle; mutant enzymes

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center